



## Original Article

# The effect of oral anticoagulant use before visit for patients with COVID-19 on mortality: A meta-analysis

Cornelia Ghea<sup>a</sup>, Ardyan Wardhana<sup>b\*</sup>, Alfredo Nugroho<sup>c</sup>, Fika Humaeda Assilmi<sup>d</sup>

<sup>a</sup>Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, <sup>b</sup>Department of Clinical Medicine, Faculty of Medicine, Universitas Surabaya, Surabaya, Indonesia, <sup>c</sup>Klinik Lombok 25, Surabaya, Indonesia, <sup>d</sup>School of Medicine, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

**Submission** : 16-Jul-2022  
**Revision** : 16-Aug-2022  
**Acceptance** : 31-Aug-2022  
**Web Publication** : 02-Nov-2022

## ABSTRACT

**Objectives:** Anticoagulants have been used as therapeutic or prophylactic agents in COVID-19 and seem to be more beneficial. However, the advantage of oral anticoagulant (OAC) consumption before visit in lowering mortality in COVID-19 patients remains debatable. This meta-analysis aimed to evaluate the effect of OAC use before visit on mortality using the hazard ratio (HR) to estimate the effect of time-to-event endpoints. **Materials and Methods:** We conducted a literature search in the PubMed and ProQuest databases for any studies comparing groups consuming OAC to no-OAC before visit for mortality in patients with COVID-19. We calculated the overall HRs and their variances across the studies using the random-effects model to obtain pooled estimates. **Results:** We included 12 studies which had sample sizes ranging from 70 to 459,402 patients. A meta-analysis comparing OAC therapy and non-OAC consumption in COVID-19 patients before visit revealed no decrease in all-cause mortality (HR = 0.92, 95% confidence interval [CI]: 0.83–1.02,  $P = 0.12$ ;  $I^2 = 68\%$ ). However, subgroup analysis of laboratory-confirmed populations revealed that OAC use before visit had a beneficial effect on mortality (HR = 0.84, 95% CI: 0.73–0.98,  $P = 0.02$ ;  $I^2 = 56\%$ ). **Conclusion:** The use of OAC before visit had no beneficial effect on all-cause mortality in COVID-19 patients.

**KEYWORDS:** Anticoagulation, COVID-19, Direct oral anticoagulant, Mortality, Oral anticoagulant

## INTRODUCTION

COVID-19 has contributed a substantial quantity of mortality. Patients with COVID-19 might also fall into a hypercoagulable state, resulting in an increased rate of thrombotic and thromboembolic events [1]. Anticoagulants have been used as therapeutic or prophylactic agents in COVID-19 and seem to be more beneficial [2]. However, the advantage of oral anticoagulant (OAC) consumption in COVID-19 patients before visit remains debatable in lowering mortality.

There has been already a meta-analysis from China comparing the effect of chronic OAC consumption on mortality in COVID-19 using the odds ratio (OR) [3]. In this meta-analysis, we aimed to evaluate the effect of OAC use before visit on all-cause mortality using the hazard ratio (HR) to estimate the effect of time-to-event endpoints. HR displayed useful statistics about how the rate of mortality is modified by OAC consumption before visit compared with the control group.

## MATERIALS AND METHODS

We selected studies involving COVID-19 patients who were on OAC before their visit. The included studies measured the mortality rate as an outcome. Any trials not comparing the OAC to non-OAC groups, not expressing the mortality rate difference as HR, or having incomplete data should be excluded.

We conducted a literature search on PubMed and ProQuest databases on March 1, 2022. We performed the following search strategy: (“coronavirus” OR “sars-cov2” OR “covid”) AND (“oral anticoagulation” OR “oral anticoagulant”) in abstract/title AND “mortality” in text. Additional records were identified from the references of the included articles. The titles and abstracts of every record from the retrieved studies obtained by applying the above search strategies were checked independently by two reviewers against the inclusion criteria.

**\*Address for correspondence:** Dr. Ardyan Wardhana, Department of Clinical Medicine, Faculty of Medicine, Universitas Surabaya, Surabaya 60293, Indonesia. E-mail: ardyanwardhana@staff.ubaya.ac.id

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Ghea C, Wardhana A, Nugroho A, Assilmi FH. The effect of oral anticoagulant use before visit for patients with COVID-19 on mortality: A meta-analysis. Tzu Chi Med J 2023;35(3):226-30.

## Access this article online

### Quick Response Code:



**Website:** www.tcmjmed.com

**DOI:** 10.4103/tcmj.tcmj\_199\_22




Figure 1: PRISMA flow diagram of this study

Subsequently, the full papers that potentially met the inclusion/exclusion criteria were reviewed by two investigators for final inclusion. The first author was the referee if there was any disputed study.

Pooled results on all-cause mortality were expressed as HRs with 95% confidence intervals (CI) by calculating the overall HRs and their variance across the studies. We only pooled HR data in the propensity score matching (PSM) study or adjusted multivariate-HR in the study without PSM. We estimated the observed and expected events (O-E events) and the variance of the natural logarithm of the HR and CI using the formula provided by Tierney *et al.* [4].

Two authors independently assessed the methodological quality assessment using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies National Institute of Health. Study Quality Assessment Tools | National Heart, Lung, and Blood Institute (NHLBI) (<https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>). The statistical package Review Manager 5.3 (RevMan 5.3) provided by the Cochrane Collaboration was used to analyze the data. A fixed-effects model and Peto OR were used for the analysis. We evaluated between-study heterogeneity using the  $I^2$  statistic. A sensitivity analysis was performed using the leave-one-out method. We performed a subgroup analysis based on admission status.

## RESULTS

After searching the literature, we found 85 articles in PubMed and 43 in the ProQuest database [Figure 1]. Two studies were retrieved from the references of the included articles. Then, we retrieved 26 full-text articles and excluded 14. The reasons for exclusion were that the result was not expressed in HR, the data were incomplete, and there was no appropriate control. Finally, 12 studies were included [5-16].

The baseline characteristics are shown in Table 1. The sample sizes of the included studies ranged from 70 to 459,402. The region came mostly from Europe, with one

study from Asia and one from the United States. Most of the included studies had a retrospective design. Hospitalized and laboratory-confirmed patients were the predominant population, with five studies each, and the remaining were emergency visit patients. All studies involved direct OAC, including rivaroxaban, apixaban, edoxaban, and dabigatran. Enoxaparin was used in only one study [12]. Only two studies did not consider warfarin [10,14].

We assessed all studies' quality based on NHLBI quality assessment resulting in good and fair methodology qualities in all included studies [Table 1]. None of the studies was seriously flawed. The analyses were rigorous, and the conclusions drawn by the studies were credible. All studies assessed exposure before outcome measurement. However, all studies did not provide a sample size justification, power description, or variance and effect estimates.

The meta-analysis comparing OAC therapy and non-OAC consumption in COVID-19 patients before visit revealed no decrease in all-cause mortality (HR = 0.92, 95% CI: 0.83–1.02,  $P = 0.12$ ;  $I^2 = 68\%$ ) [Figure 2a]. A similar result was shown if we only pooled data from PSM studies (HR = 0.97, 95% CI: 0.85–1.11,  $P = 0.69$ ;  $I^2 = 71\%$ ) [Figure 2b]. Analysis of the study using adjusted multivariate HR also showed similar results (HR = 0.95, 95% CI: 0.87–1.04,  $P = 0.29$ ;  $I^2 = 71\%$ ) [Figure 2c].

Sensitivity analysis showed the same result without improvement in heterogeneity (HR = 0.95, 95% CI: 0.85–1.05,  $P = 0.30$ ;  $I^2 = 61\%$ ). Analysis of the hospital admission and emergency department visit subgroup reported similar results to the total group [Figure 3]. However, subgroup analysis of laboratory-confirmed populations revealed that OAC use before visit had a beneficial effect on mortality (HR = 0.84, 95% CI: 0.73–0.98,  $P = 0.02$ ;  $I^2 = 56\%$ ).

## DISCUSSION

The main finding of this meta-analysis was that consumption of OAC before visit had no benefit in reducing all-cause mortality in patients with COVID-19. This was similar to the findings of a previous meta-analysis that used pooled data of OR [3]. Analysis using HR in this meta-analysis provided how OAC use before admission changes the mortality rates and not just determines if there is an association between OAC use before admission and mortality. This showed that the risk of an individual in the OAC group was similar to that of an individual in the non-OAC group at any given time interval.

It was suspected that patients taking OAC before visit had a higher risk of mortality due to comorbidities and advancing age. However, this meta-analysis suggested that there was no difference in mortality between patients on OACs versus those without OACs before visit when compared in an adjusted multivariate analysis or in a PSM analysis. This analysis was corrected for confounding effects, such as underlying comorbidities and advancing age. However, it was not possible to perform complete matching for all conditions, such as atrial fibrillation with or without stroke, history of venous thromboembolism, and mechanical heart valves.

Table 1: Baseline characteristic of the included studies

First author	Country	Registry	Year	Study design	Population	Sample size	Sex (%)	Age (years)	OAC agent	Outcome	Study quality
Arachchillage	UK	UK NHS trusts	2020	Retrospective and prospective	Hospital admission	5883	Male 55.2	74 (56-84)	DOAC, VKA	No difference in mortality [aHR: 1.05 (95% CI 0.93-1.19); $P=0.15$ ]	Good
Buenen	Netherlands	Bernhoven Hospital, Uden	2020	Prospective	Emergency department visit	497	Male 64	72	DOAC, VKA	Reduction in risk for mortality [aHR: 0.64 (95% CI 0.42-0.96); $P=0.03$ ]	Fair
Chocron	French	Critical COVID-19, France	2020	Retrospective	Hospital admission	2878	Male 57.9	66.63±16.96	DOAC, VKA	Reduction in risk for mortality [aHR: 0.70 (95% CI 0.55-0.88); $P=0.003$ ]	Good
Covino	Italy	An urban teaching hospital	2020	Prospective	Emergency department visit	2666	Male 50	84 (81-87)	DOAC, VKA	Increased risk of mortality [aHR: 1.56 (95% CI: 0.78-3.12); $P=0.208$ ]	Good
Denas	Italy	Veneto Region	2020	Retrospective	Laboratory confirmed	4697	Male 50.1	≥65	DOAC, VKA	Reduction in risk for mortality [PSM-HR: 0.81 (95% CI: 0.65-1.01); $P=0.054$ ]	Fair
Flam	Sweden	Nationwide Swedish Register	2020	Retrospective	Laboratory confirmed	459,402	Male 65.6	73.6±7.6	DOAC	No difference in mortality [aHR: 0.91 (95% CI: 0.70-1.18)]	Good
Guleu	Turkey	No information	2020	Retrospective	Hospital admission	5575	Male 50.2	64 (51-74)	DOAC, VKA	Reduction in risk for mortality [aHR: 0.62 (95% CI: 0.42-0.92), $P=0.03$ ]	Fair
Hozayen	USA	M Health Fairview system	2020	Prospective	Laboratory confirmed	6195	Male 43	50.68±22.15	DOAC, VKA, enoxaparin	No difference in mortality [aHR: 0.88 (95% CI 0.50-1.52); $P=0.64$ ]	Good
Rivera-caravaca	Ecuador, Germany, Italy, Spain	HOPE Registry	2020	Retrospective	Hospital admission	1002	Male 60.9	81.5 (75-87)	DOAC, VKA	Increased risk of mortality [PSM-HR: 1.53 (95% CI: 1.08-2.16)]	Good
Rossi	Italy	Policlinico of Modena	2020	Retrospective	Laboratory confirmed	70	Male 50	79 (70-92)	DOAC	Reduction in risk for mortality [aHR: 0.38 (95% CI: 0.17-0.58)]	Fair
Russo	Italy	Six Italian Hospitals	2020	Retrospective	Hospital admission	427	Male 63	67±14	DOAC, VKA	No difference in mortality [aHR: 1.07 (95% CI: 0.66-1.73)]	Fair
Tremblay	USA	New York City health system	2020	Retrospective	Laboratory confirmed	3772	Male 54.8	56.6±18.2	DOAC, VKA	No difference in mortality [PSM-HR: 1.21 (95% CI: 0.75-1.95); $P=0.37$ ]	Fair

OAC: Oral anticoagulant, DOAC: Direct OAC, VKA: Vitamin K antagonists, aHR: Adjusted hazard ratio, CI: Confidence interval, IQR: Interquartile range, PSM: Propensity score matching




Figure 2: Forest plot in all included studies (a). Forest plot in PSM studies (b). Forest plot in adjusted multivariate studies (c)




Figure 3: Forest plot in subgroup analysis based on admission status

Thrombosis characterized by increased D-dimer levels in patients with COVID-19 were associated with increased risk of mortality [17,18]. It has been postulated that systemic inflammation and activation of the complement system contribute to the hypercoagulable condition and dysfunction of the endothelium, leading to microvascular thrombosis and consequent increased risk of mortality in COVID-19 [19,20].

Because it has no anti-inflammatory properties, OAC has no effect on the mortality of patients with COVID-19. It differs from heparin in that it can potentially reduce the activation of inflammatory responses [21].

Different results were observed in the subgroup analysis of the laboratory-confirmed patient population. This population



comprised most outpatients. This finding suggests that patients not requiring admission for COVID-19 might benefit from chronic OAC consumption before contracting COVID-19. One report demonstrated that anticoagulation in the early phase of COVID-19 may be beneficial in selected patients [22].

This study has a few limitations. First, heterogeneity was significantly high. We included not only various populations from outpatients to inpatients but also various comorbidities. Most of the included studies were also prospective studies; therefore, they lacked control on cofactors that may affect the outcome. Second, the included studies did not control for the duration of OAC before admission, duration, or the dose regimen of anticoagulation during admission, which could have been a confounding bias. Later, there were probably more studies that not included in our meta-analysis as we have only used two databases.

## CONCLUSION

This meta-analysis revealed that OAC use before visit had no beneficial effect on the all-cause mortality of COVID-19 patients. This analysis corrected for confounding effects such as underlying comorbidities and advancing age because it pooled data only from PSM or adjusted multivariate studies. Patients at risk of thrombovenous events should continue anticoagulation because outpatients may benefit from chronic anticoagulation if they contract COVID-19.

## Data availability statement

All data generated or analyzed during this study are included in this published article.

## Acknowledgment

This study was performed as part of Ardyan Wardhana employment at the Faculty of Medicine, Universitas Surabaya, Indonesia.

## Financial support and sponsorship

This work did not receive specific funding, and as part of Cornelia Ghea study at Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J, et al. COVID-19 and hypercoagulability: A review. *Clin Appl Thromb Hemost* 2020;26:1076029620962853.
- Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: A systematic review and an updated meta-analysis. *Semin Thromb Hemost* 2021;47:372-91.
- Zeng J, Liu F, Wang Y, Gao M, Nasr B, Lu C, et al. The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: A systematic review and meta-analysis. *Am J Emerg Med* 2022;54:107-10.
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;8:16.
- Arachchilage DJ, Rajakaruna I, Odho Z, Crossette-Thambiah C, Nicolson PL, Roberts LN, et al. Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK: A multicentre observational study. *Br J Haematol* 2022;196:79-94.
- Buenen AG, Sinkeldam M, Maas ML, Verdonchot M, Wever PC. Prior use of anticoagulation is associated with a better survival in COVID-19. *J Thromb Thrombolysis* 2021;52:1207-11.
- Chocron R, Galand V, Cellier J, Gendron N, Pommier T, Bory O, et al. Anticoagulation before hospitalization is a potential protective factor for COVID-19: Insight from a French multicenter cohort study. *J Am Heart Assoc* 2021;10:e018624.
- Covino M, De Matteis G, Della Polla D, Burzo ML, Pascale MM, Santoro M, et al. Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? *Aging Clin Exp Res* 2021;33:2335-43.
- Denas G, Gennaro N, Ferroni E, Fedeli U, Lorenzoni G, Gregori D, et al. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. *Int J Cardiol* 2021;329:266-9.
- Flam B, Wintzell V, Ludvigsson JF, Mårtensson J, Pasternak B. Direct oral anticoagulant use and risk of severe COVID-19. *J Intern Med* 2021;289:411-9.
- Gülcü O, Aksakal E, Aydemir S, Doğan R, Saraç İ, Aydın SŞ, et al. Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19. *J Thromb Thrombolysis* 2022;53:88-95.
- Hozayen SM, Zychowski D, Benson S, Lutsey PL, Haslbauer J, Tzankov A, et al. Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. *EClinicalMedicine* 2021;41:101139.
- Rivera-Caravaca JM, Núñez-Gil JJ, Vivas D, Viana-Llamas MC, Uribarri A, Becerra-Muñoz VM, et al. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. *Eur J Clin Invest* 2021;51:e13436.
- Rossi R, Coppi F, Talarico M, Boriani G. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. *Eur J Intern Med* 2020;77:158-60.
- Russo V, Bottino R, D'Andrea A, Silverio A, Di Maio M, Golino P, et al. Chronic oral anticoagulation and clinical outcome in hospitalized COVID-19 patients. *Cardiovasc Drugs Ther* 2022;36:705-12.
- Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, et al. Impact of anticoagulation prior to COVID-19 infection: A propensity score-matched cohort study. *Blood* 2020;136:144-7.
- Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. *EClinicalMedicine* 2020;29:100639.
- Nugroho J, Wardhana A, Maghfirah I, Mulia EP, Rachmi DA, A'yun MQ, et al. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients: A meta-analysis. *Int J Lab Hematol* 2021;43:110-5.
- Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *J Thromb Haemost* 2020;18:1559-61.
- Scudiero F, Silverio A, Di Maio M, Russo V, Citro R, Personeni D, et al. Pulmonary embolism in COVID-19 patients: Prevalence, predictors and clinical outcome. *Thromb Res* 2021;198:34-9.
- Buijssers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. *EBioMedicine* 2020;59:102969.
- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost* 2020;18:1094-9.



ISSN 1744-5019 (print)  
ISSN 1744-5027 (online)

Journal of the Buddhist Compassion  
Society For Health Promotion

# TZU CHI MEDICAL JOURNAL



Volume 13 Number 1  
June September 2023

ISSN 1744-5019

Page 1

Published by Tzu Chi Medical Journal Society, Buddhist Compassion  
Society For Health Promotion, Tzu Chi University  
www.tzu-chi-medical-journal.com

Printed in Taiwan



# Editorial Board : Tzu Chi Medical Journal

Advertisement

## Editorial Board

### EDITOR-IN-CHIEF

The Editor-in-Chief is the most senior editor who takes the overall responsibility of the journal. The Editor-in-Chief carries out the administrative responsibilities of the journal, planning of the journal style and content, makes the final decisions of the reviewed articles, and resolves the complains or appeals to the journal.

Prof (Dr) Hann-Chorng Kuo,  
Professor,

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan  
E-mail: [hck@tzuchi.com.tw](mailto:hck@tzuchi.com.tw)

### Executive Associate Editors

The associate editors are responsible for the primary evaluation of the submitted manuscripts for journal suitability, selecting the section editors from the board members, coordinating the peer review process, and making the initial evaluation of the revised manuscript. The associate editors also contribute to the planning of the journal content, researching topics for editorial, and involving in special issue editorial.

Dr. Raymond Y. Lo,  
Associate Professor,

Department of Neurology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan  
E-mail: [rayyenyu@hotmail.com](mailto:rayyenyu@hotmail.com)

Prof. Chih-Wen Peng,  
Professor,

Department of Life Science, National Dong Hwa University, Hualien, Taiwan  
E-mail: [pengcw@ndhu.edu.tw](mailto:pengcw@ndhu.edu.tw)

### Associate Editors

The associated and section sectors are experts in sub-specialties in the clinical medicine and basic science. They provide evaluation and expert opinions to the submitted manuscript in different sub-specialties, selecting reviewers from the reviewer board members, evaluating the comments from the internal peer reviewers, and making the initiation decision on the revised manuscript.

Prof (Dr) You-Chen Chao,  
Professor,  
Department of Gastroenterology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei,  
Taiwan  
E-mail: chaoycmd@tzuchi.com.tw

Dr. Sou-Hsin Chien,  
Associate Professor,  
Department of Plastic Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung,  
Taiwan  
E-mail: shchien@tzuchi.com.tw

Prof (Dr) Ning-Sheng Lai,  
Professor,  
Department of Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan  
E-mail: Q12015@tzuchi.com.tw

Prof (Dr) Shinn-Zong Lin,  
Professor,  
Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien,  
Taiwan  
E-mail: Shinn-Zong@tzuchi.com.tw

Prof (Dr) Pen-Jung Wang,  
Professor,  
Department of Pediatrics, Tzu Chi University, Hualien, Taiwan  
E-mail: pedwpj@mail.tcu.edu.tw

**Section Editors** The associated and section sectors are experts in sub-specialties in the clinical medicine and basic science. They provide evaluation and expert opinions to the submitted manuscript in different sub-specialties, selecting reviewers from the reviewer board members, evaluating the comments from the internal peer reviewers, and making the initiation decision on the revised manuscript.

Prof (Dr) Chung-Hsing Chang  
Professor,  
Department of Dermatology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Dr. En-Ting Chang  
Associate Professor,  
Department of Chest, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof. Hsin-Hou Chang,  
Professor,  
Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan

Prof (Dr) Yao-Jen Chang,  
Professor,  
Department of General Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei,  
Taiwan

Prof (Dr) Chien-Lin Chen,  
Professor,  
Department of Gastroenterology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien,  
Taiwan

Hao-Ping Chen, PhD  
Associate Professor,



Department of Biochemistry, Tzu Chi University, Hualien, Taiwan

Prof (Dr) Ing-Ho Chen,  
Professor,  
Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Peir-Rong Chen,  
Professor,  
Department of Otolaryngology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Shin-Yuan Chen,  
Professor,  
Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Tsung-Ying Chen,  
Professor,  
Department of Anesthesiology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Ching-Feng Cheng,  
Professor,  
Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

Prof Ted H. Chiu,  
Professor,  
Department of Pharmacology, Tzu Chi University, Hualien, Taiwan

Dr. Shao-Yin Chu,  
Assistant Professor,  
Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Dah-Ching Ding,  
Professor,  
Department of Obstetrics & Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Te-Chao Fang,  
Professor,  
Department of Nephrology, Taipei Municipal Wanfang Hospital, Taipei, Taiwan

Han-Chen Ho, PhD,  
Associate Professor,  
Department of Anatomy, Tzu Chi University, Hualien, Taiwan

Dr. Jong-Kai Hsiao,  
Associate Professor,  
Department of Medical Imaging, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

Tsung-Cheng Hsieh, PhD,  
Associate Professor,  
Department of Public Health, Tzu Chi University, Hualien, Taiwan

Prof (Dr) Bang-Gee Hsu,  
Professor,  
Department of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Dr. Honda Hsu,  
Assistant Professor,  
Department of Plastic Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan

Prof (Dr) Yung-Hsiang Hsu,  
Professor,  
Department of Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Juen-Haur Hwang,  
Professor,  
Department of Otolaryngology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan

Dr. Yuan-Hong Jiang,  
Assistant Professor,  
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Yu-Lin Ko,  
Professor,  
Department of Cardiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

Dr. Ko-Lin Kuo,  
Associate Professor,  
Department of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

Prof (Dr) Hong-Shiee Lai,  
Professor,  
Department of General Surgery, National Taiwan University Hospital, Taipei, Taiwan

Prof Hui-Ling Lai  
Professor,  
Department of Nursing, Tzu Chi University, Hualien, Taiwan

Prof (Dr) Ming-Che Lee,  
Professor,  
Department of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof (Dr) Chun-Hou Liao,  
Professor,  
Department of Urology, Cardinal Tien Hospital, New Taipei, Taiwan

Dr. Chaucer C.H. Lin,  
Assistant Professor,  
Department of Psychiatry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof. Chao-Zong Liu,  
Professor,  
Department of Pharmacology, Tzu Chi University, Hualien, Taiwan

Prof. Ingrid Yi-Chun Liu,  
Professor,  
Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan

Prof. Shih-Yen Lo,  
Professor,  
Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien, Taiwan

Shu-Fen Lo, PhD,  
Associate Professor,  
Department of Nursing, Tzu Chi University of Science and Technology, Hualien, Taiwan

Prof (Dr) Ming-Chi Lu,  
Professor,  
Department of Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan

Prof. Ahai-C. Lua,  
Professor,  
(epartment of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien, Taiwan

Prof. Kun-Ruey Shieh,  
Professor,  
Department of Physiology, Tzu Chi University, Hualien, Taiwan

Prof. Chuan-Hsiu Tsai,  
Professor,  
Department of Nursing, Tzu Chi University, Hualien, Taiwan

Prof (Dr) Rong-Kung Tsai,  
Professor,  
Department of Ophthalmology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Dr. Chen-Chie Wang,  
Associate Professor,  
Department of Orthopedics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

Prof. Shu-Hui Wen,  
Professor,  
Department of Public Health, Tzu Chi University, Hualien, Taiwan

Dr. Ji-Hi Yeh,  
Associate Professor,  
Department of Family Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Prof. Chia-Feng Yen,  
Professor,  
Department of Public Health, Tzu Chi University, Hualien, Taiwan

Dr. Giou-Teng Yiang,  
Associate Professor,  
Department of Emergency Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan

### **International Editorial Board**

The international editors are invited editors from the world wide countries who have special contribution and expertise in the clinical medicine or basic science. They provide initial evaluation and expert opinions to the submitted manuscript in their sub-specialties, evaluating the comments from the internal peer reviewers, and making the initiation decision on the revised manuscript.

Prof (Dr) Koji Abe,  
Professor,  
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry  
and Pharmaceutical Science, Okayama, Japan

Prof. Malcolm Alison,  
Professor,  
Barts Cancer Institute, Queen Mary University of London, London, UK

Prof (Dr) Anish Bhardwaj,  
Professor,  
Department of Biological Science, Tufts University School of Medicine, Boston, MA,  
USA

Prof (Dr) Michael B. Chancellor,  
Professor,  
Department of Urology, Oakland University William Beaumont School of Medicine,  
Rochester, MI, USA

Prof. Chawnshang Chang,  
Professor,  
George Whipple Laboratory for Cancer Research, Department of Pathology, University of  
Rochester, Rochester, NY, USA

Prof. Nae J. Dun,  
Professor,  
Department of Pharmacology, Lewis Katz School of Medicine, Temple University,  
Philadelphia, PA, USA

Prof. Tomoyuki Kuwaki,  
Professor,  
Department of Physiology, Graduate School of Medical and Dental Sciences, Kagoshima  
University, Kagoshima, Japan

Prof. Jung-Chung Lin,  
Professor,  
Centers for Disease Control and Prevention, USA

Prof (Dr) Marek Alexander Z Mirski,  
Professor,  
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University,  
Baltimore, USA)

Prof (Dr) Peter C. Neligan,  
Professor,  
Center for Reconstructive Surgery at UWMC, Seattle, Wash, University of Washington,  
USA

Prof (Dr) Hriday N. Sapru,  
Professor,  
Department of Neurological Surgery, UMDNJ-New Jersey Medical School, NJ, USA

Prof. Nick Wright,  
Professor,  
Queen Mary, University of London, UK

**Publisher**

Buddhist Compassion Relief Tzu Chi Foundation

Honorary Publishing Supervisor: Master Cheng Yen  
Publishing Supervisor: Chin-Lon Lin  
No. 707, Section 3, Chung-Yang Road, Hualien, Taiwan  
Advertisement

^Back to Top



## Never Miss an Issue

Get new journal Tables of Contents sent right to your email inbox

[Get New Issue Alerts](#)

## Browse Journal Content


- [Register on the website](#)
- [Subscribe](#)
- [Get eTOC Alerts](#)

## Customer Service

- Contact us at:
  - Support:  
[Submit a Service Request](#)
  - TEL:  
800-638-3030 (within the USA)  
301-223-2300 (outside of the USA)

[Manage Cookie Preferences](#)

- [Privacy Policy](#)
- [Legal Disclaimer](#)
- [Terms of Use](#)

- [Open Access Policy](#)
- [Your California Privacy Choices](#) 
- Copyright © 2024
- Tzu Chi Medical Journal | Published by Wolters Kluwer - [Medknow](#)

Advertisement

Close



# Jul-Sep 2023 - Volume 35 - Issue 3 : Tzu Chi Medical Journal

[Home](#) > Jul-Sep 2023 - Volume 35 - Issue 3

[Previous Issue](#) | [Next Issue](#)



Jul-Sep 2023 - Volume 35 - Issue 3

pp: 205-277

[Table of Contents Outline](#)

[eTOC Alerts](#)

[Contributor Index](#)

☐ **Review Article**

---

## [Pathophysiology, clinical presentation, and management of ketamine-induced cystitis](#)

Jhang, Jia-Fong; Birder, Lori A.; Kuo, Hann-Chorng

Tzu Chi Medical Journal. 35(3):205-212, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)

- [Open](#)

### **[Coronavirus disease 2019 and cardiovascular disease](#)**

Song, Jenn-Yeu; Huang, Jian-You; Hsu, Yi-Chiung; More

Tzu Chi Medical Journal. 35(3):213-220, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

[Table of Contents Outline](#) | [Back to Top](#)

## **☐ Original Article**

---

### **[The effects of rehabilitation on functional independence of Eastern Taiwanese children with rare or genetic diseases](#)**

Lin, Yu-Chuan; Weng, Chun-Ying; Liang, Chung-Chao; More

Tzu Chi Medical Journal. 35(3):221-225, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **[The effect of oral anticoagulant use before visit for patients with COVID-19 on mortality: A meta-analysis](#)**

Ghea, Cornelia; Wardhana, Ardyana; Nugroho, Alfredo; More

Tzu Chi Medical Journal. 35(3):226-230, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **[Finite element analysis to assess stress and deformation in bone with glass fiber-reinforced-poly-ether-ether-ketone, zirconia, and titanium implants](#)**

Haseeb, Syeda Amtul; Kumar, Anju S; Chaitra, M. P.; More

Tzu Chi Medical Journal. 35(3):231-236, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **Percutaneous endoscopic lumbar discectomy versus open lumbar microdiscectomy for treating lumbar disc herniation: Using the survival analysis**

Lin, Chang-Hao; Huang, Yi-Hung; Lien, Fang-Chieh; More

Tzu Chi Medical Journal. 35(3):237-241, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **An innovation percutaneous needle knife use for trigger finger: A retrospective cohort study**

Velmurugan, Bharath Kumar; Huang, Chih-Yang; Ding, Dah-Ching; More

Tzu Chi Medical Journal. 35(3):242-246, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **Previous nonhepatectomy abdominal surgery did not increase the difficulty in laparoscopic hepatectomy for hepatocellular carcinoma: A case–control study in 100 consecutive patients**

Lee, Yi-Hsuan; Lin, Hsiu-Hsien; Kuo, Tsai-Ling; More

Tzu Chi Medical Journal. 35(3):247-252, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **The differences in the adrenergic receptors of proximal urethra between sexes**

Hsieh, Po-Chun; Chang, Shang-Jen; Chang, Hsi-Hsien; More

Tzu Chi Medical Journal. 35(3):253-259, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **Nurse-led coaching of shared decision-making for wound treatment of pressure injury: A pilot study of a randomized trial**

Hsu, Mei-Yu; Chen, Yu-Sin; Chen, Ying-Chun; More

Tzu Chi Medical Journal. 35(3):260-266, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

### **Reliability and validity of the Taiwanese version of the collaborative practice assessment tool: A pilot study**

Ho, Chen-Pei; Yeh, Hsiu-Chen; Lee, Ming-Shinn; More

Tzu Chi Medical Journal. 35(3):267-276, Jul-Sep 2023.

- [Abstract](#)
- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)

[Table of Contents Outline](#) | [Back to Top](#)

## **☐ Corrigendum**

---

### **Corrigendum: Comparison of surgical outcome between conventional open thyroidectomy and endoscopic thyroidectomy through axillo-breast approach**

Tzu Chi Medical Journal. 35(3):277, Jul-Sep 2023.

- [Favorite](#)
- [PDF](#)
- [Permissions](#)
- [Open](#)
- [Erratum](#)

^Back to Top



## Never Miss an Issue

Get new journal Tables of Contents sent right to your email inbox

[Get New Issue Alerts](#)

## Browse Journal Content

- [Register on the website](#)
- [Subscribe](#)
- [Get eTOC Alerts](#)

## Customer Service

- Contact us at:
  - Support:  
[Submit a Service Request](#)
  - TEL:  
800-638-3030 (within the USA)  
301-223-2300 (outside of the USA)

[Manage Cookie Preferences](#)

- [Privacy Policy](#)
- [Legal Disclaimer](#)

- [Terms of Use](#)
- [Open Access Policy](#)

- [Your California Privacy Choices](#)



- Copyright © 2024
- Tzu Chi Medical Journal | Published by Wolters Kluwer - [Medknow](#)

Advertisement

Close



## Tzu Chi Medical Journal

### COUNTRY

India

 Universities and research institutions in India

 Media Ranking in India

### SUBJECT AREA AND CATEGORY

Medicine

Medicine (miscellaneous)

### PUBLISHER

Wolters Kluwer Medknow Publications

### H-INDEX

23

### PUBLICATION TYPE

Journals

### ISSN

10163190

### COVERAGE

1997-2022

### INFORMATION

[Homepage](#)

[How to publish in this journal](#)


[hck@tzuchi.com.tw](mailto:hck@tzuchi.com.tw)

### SCOPE

Tzu Chi Medical Journal, a publication of Buddhist Compassion Relief Tzu Chi Foundation, is a peer-reviewed online journal with Quarterly print on demand compilation of issues published. The journal's full text is available online at <http://www.tcmjmed.com>. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.

 Join the conversation about this journal

1 <b>National Medical Journal of China</b> CHN	2 <b>Medicine (United States)</b> USA	3 <b>Journal of International Medical Research</b> GBR	4 <b>Therapeutics and Clinical Risk Management</b> NZL	5 <b>International Journal of General Medicine</b> NZL
48% similarity	47% similarity	47% similarity	45% similarity	45% similarity



← Show this widget in your own website

Just copy the code below and paste within your html code:

`<a href="https://www.scimagojr.com">`

### SCImago Graphica

Explore, visually communicate and make sense of data with our [new data visualization tool](#).



Metrics based on Scopus® data as of April 2023

Y **Yehya** 4 months ago  
Could you clarify if this journal is free of charge?  
reply



**Melanie Ortiz** 4 months ago

Dear Yehya,  
Thank you for contacting us.  
We suggest you visit the journal's homepage or contact the journal's editorial staff, so they could inform you more deeply.  
Best Regards, SCImago Team

SCImago Team

Name

Email

(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

---

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS  
Holland (Before 1.1.1995)

[Legal Notice](#)

[Privacy Policy](#)

---





# Source details

## Tzu Chi Medical Journal

Open Access ⓘ

Scopus coverage years: from 1997 to 2023

Publisher: Wolters Kluwer Health

ISSN: 1016-3190

Subject area: Medicine: General Medicine

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2022  
**2.5** ⓘ

SJR 2022  
**0.358** ⓘ

SNIP 2022  
**0.715** ⓘ

[CiteScore](#)   [CiteScore rank & trend](#)   [Scopus content coverage](#)

CiteScore

2022

2.5

=

625 Citations 2019 - 2022

248 Documents 2019 - 2022

Calculated on 05 May, 2023

CiteScoreTracker 2023 ⓘ

3.2

=

762 Citations to date

235 Documents to date

Last updated on 05 January, 2024 • Updated monthly

### CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Medicine		
General Medicine	#328/830	60th

[View CiteScore methodology >](#)   [CiteScore FAQ >](#)   [Add CiteScore to your site](#)

---

## About Scopus

- What is Scopus
- Content coverage
- Scopus blog
- Scopus API
- Privacy matters

## Language

- 日本語版を表示する
- 查看简体中文版本
- 查看繁體中文版本
- Просмотр версии на русском языке

## Customer Service

- Help
- Tutorials
- Contact us

---

## ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

All content on this site: Copyright © 2024 Elsevier B.V. ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply. We use cookies to help provide and enhance our service and tailor content.By continuing, you agree to the use of cookies ↗.

